In Silico Design and Evaluation of PRAME+FliCΔD2D3 as a New Breast Cancer Vaccine Candidate.

ABSTRACT:

Background

The most prevalent cancer in women over the world is breast cancer. Immunotherapy is a promising method to effectively treat cancer patients. Among various immunotherapy methods, tumor antigens stimulate the immune system to eradicate cancer cells. Preferentially expressed antigen in melanoma (PRAME) is mainly overexpressed in breast cancer cells, and has no expression in normal tissues. FliCΔD2D3, as truncated flagellin (FliC), is an effective toll-like receptor 5 (TLR5) agonist with lower inflammatory responses. The objective of the present study was to utilize bioinformatics methods to design a chimeric protein against breast cancer.

Methods

The physicochemical properties, solubility, and secondary structures of PRAME+FliCΔD2D3 were predicted using the tools Pr

SUBMITTER: Taheri-Anganeh M 

PROVIDER: S-EPMC7812496 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature